19-334 - Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

Status: open

A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA

Treatment for Melanoma

Contact Us Or call (251) 445-9834

Description

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

Sponsors

This trial is sponsored by SWOG.

Principle Investigator

Providers Associated With This Trial

This link will open in a new tab or window.